Literature DB >> 28555386

Molecular pathogenesis of viral hemorrhagic fever.

Christopher F Basler1.   

Abstract

The clinical syndrome referred to as viral hemorrhagic fever (VHF) can be caused by several different families of RNA viruses, including select members of the arenaviruses, bunyaviruses, filoviruses, and flaviviruses. VHF is characterized by malaise, fever, vascular permeability, decreased plasma volume, coagulation abnormalities, and varying degrees of hemorrhage. Study of the filovirus Ebola virus has demonstrated a critical role for suppression of innate antiviral defenses in viral pathogenesis. Additionally, antigen-presenting cells are targets of productive infection and immune dysregulation. Among these cell populations, monocytes and macrophages are proposed to produce damaging inflammatory cytokines, while infected dendritic cells fail to undergo proper maturation, potentially impairing adaptive immunity. Uncontrolled virus replication and accompanying inflammatory responses are thought to promote vascular leakage and coagulopathy. However, the specific molecular pathways that underlie these features of VHF remain poorly understood. The arenavirus Lassa virus and the flavivirus yellow fever virus exhibit similar molecular pathogenesis suggesting common underlying mechanisms. Because non-human primate models that closely mimic VHF are available for Ebola, Lassa, and yellow fever viruses, we propose that comparative molecular studies using these models will yield new insights into the molecular underpinnings of VHF and suggest new therapeutic approaches.

Entities:  

Keywords:  Ebola virus; Hemorrhagic fever; Lassa virus; yellow fever virus

Mesh:

Substances:

Year:  2017        PMID: 28555386      PMCID: PMC6436832          DOI: 10.1007/s00281-017-0637-x

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   9.623


  105 in total

Review 1.  Dendritic cells: specialized and regulated antigen processing machines.

Authors:  I Mellman; R M Steinman
Journal:  Cell       Date:  2001-08-10       Impact factor: 41.582

2.  Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus.

Authors:  Delphine Pannetier; Stéphanie Reynard; Marion Russier; Alexandra Journeaux; Noël Tordo; Vincent Deubel; Sylvain Baize
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

3.  Ebolaviruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages.

Authors:  Judith Olejnik; Adriana Forero; Laure R Deflubé; Adam J Hume; Whitney A Manhart; Andrew Nishida; Andrea Marzi; Michael G Katze; Hideki Ebihara; Angela L Rasmussen; Elke Mühlberger
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

Review 4.  Yellow fever: an update.

Authors:  T P Monath
Journal:  Lancet Infect Dis       Date:  2001-08       Impact factor: 25.071

5.  Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.

Authors:  Thomas W Geisbert; Lisa E Hensley; Peter B Jahrling; Tom Larsen; Joan B Geisbert; Jason Paragas; Howard A Young; Terry M Fredeking; William E Rote; George P Vlasuk
Journal:  Lancet       Date:  2003-12-13       Impact factor: 79.321

6.  Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection.

Authors:  F Villinger; P E Rollin; S S Brar; N F Chikkala; J Winter; J B Sundstrom; S R Zaki; R Swanepoel; A A Ansari; C J Peters
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

7.  Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome.

Authors:  Priya Luthra; Parameshwaran Ramanan; Chad E Mire; Carla Weisend; Yoshimi Tsuda; Benjamin Yen; Gai Liu; Daisy W Leung; Thomas W Geisbert; Hideki Ebihara; Gaya K Amarasinghe; Christopher F Basler
Journal:  Cell Host Microbe       Date:  2013-07-17       Impact factor: 21.023

8.  A prospective study of the epidemiology and ecology of Lassa fever.

Authors:  J B McCormick; P A Webb; J W Krebs; K M Johnson; E S Smith
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

9.  Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery.

Authors:  Tsung-Hsien Chang; Toru Kubota; Mayumi Matsuoka; Steven Jones; Steven B Bradfute; Mike Bray; Keiko Ozato
Journal:  PLoS Pathog       Date:  2009-06-26       Impact factor: 6.823

10.  Assessing the Evidence Supporting Fruit Bats as the Primary Reservoirs for Ebola Viruses.

Authors:  Siv Aina J Leendertz; Jan F Gogarten; Ariane Düx; Sebastien Calvignac-Spencer; Fabian H Leendertz
Journal:  Ecohealth       Date:  2015-08-13       Impact factor: 3.184

View more
  29 in total

1.  The Induction of IL-1β Secretion Through the NLRP3 Inflammasome During Ebola Virus Infection.

Authors:  Peter Halfmann; Lindsay Hill-Batorski; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

Review 2.  Clinical Evaluation of Ebola Virus Disease Therapeutics.

Authors:  Guodong Liu; Gary Wong; Shuo Su; Yuhai Bi; Frank Plummer; George F Gao; Gary Kobinger; Xiangguo Qiu
Journal:  Trends Mol Med       Date:  2017-08-17       Impact factor: 11.951

3.  Endothelial Dysfunction as a Primary Consequence of SARS-CoV-2 Infection.

Authors:  Genevieve Mezoh; Nigel J Crowther
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Severe Yellow Fever and Extreme Hyperferritinemia Managed with Therapeutic Plasma Exchange.

Authors:  Jaques Sztajnbok; Ceila Maria Sant'Ana Malaque; Camila Hitomi Nihei; Irene Faria Duayer; Zita Maria Leme Britto; Eduarda Gambini Beraldo; Ralcyon Francis AzevedoTeixeira
Journal:  Am J Trop Med Hyg       Date:  2019-09       Impact factor: 2.345

5.  Adipocytes are susceptible to Ebola Virus infection.

Authors:  Francoise A Gourronc; Michael R Rebagliati; Breanna Kramer-Riesberg; Anthony M Fleck; J J Patten; Kathleen Geohegan-Barek; Kelly N Messingham; Robert A Davey; Wendy Maury; Aloysius J Klingelhutz
Journal:  Virology       Date:  2022-05-27       Impact factor: 3.513

Review 6.  Platelets in Viral Infections - Brave Soldiers or Trojan Horses.

Authors:  Waltraud C Schrottmaier; Anna Schmuckenschlager; Anita Pirabe; Alice Assinger
Journal:  Front Immunol       Date:  2022-03-28       Impact factor: 7.561

7.  Fatal Puumala Hantavirus Disease: Involvement of Complement Activation and Vascular Leakage in the Pathobiology.

Authors:  Tarja Sironen; Jussi Sane; Marja-Liisa Lokki; Seppo Meri; Leif C Andersson; Timo Hautala; Heikki Kauma; Sakari Vuorinen; Johan Rasmuson; Magnus Evander; Clas Ahlm; Antti Vaheri
Journal:  Open Forum Infect Dis       Date:  2017-10-21       Impact factor: 3.835

8.  Prothrombin Time, Activated Partial Thromboplastin Time, and Fibrinogen Reference Intervals for Inbred Strain 13/N Guinea Pigs (Cavia porcellus) and Validation of Low Volume Sample Analysis.

Authors:  Jillian A Condrey; Timothy Flietstra; Kaitlyn M Nestor; Elizabeth L Schlosser; JoAnn D Coleman-McCray; Sarah C Genzer; Stephen R Welch; Jessica R Spengler
Journal:  Microorganisms       Date:  2020-07-27

9.  Lassa virus activates myeloid dendritic cells but suppresses their ability to stimulate T cells.

Authors:  Justine Schaeffer; Xavier Carnec; Stéphanie Reynard; Mathieu Mateo; Caroline Picard; Natalia Pietrosemoli; Marie-Agnès Dillies; Sylvain Baize
Journal:  PLoS Pathog       Date:  2018-11-12       Impact factor: 6.823

Review 10.  Viruses go modular.

Authors:  Ariel Shepley-McTaggart; Hao Fan; Marius Sudol; Ronald N Harty
Journal:  J Biol Chem       Date:  2020-02-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.